AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. Our two Research & Development (R&D) organisations - R&D BioPharmaceuticals, responsible for Cardiovascular, Renal and Metabolism and Respiratory diseases, and opportunistically driven for Neuroscience and Microbial Sciences and R&D Oncology, enable us to follow the science through drug discovery and development, and life-cycle management programmes.
Each year we invest $5.9bn in our science, discovering and developing the next generation of life changing medicines. To put ourselves in the best position to push the boundaries of science, we seek to leverage our combination of capabilities, which encompass both small molecules, oligonucleotides and other emerging drug platforms, as well as biologics, including immunotherapies, and innovative delivery devices that can offer choice to patients.
